title: AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression.
authors.forename: Leandro
authors.initials: L
authors.lastname: Kasuki
authors.forename: Leonardo
authors.initials: L
authors.lastname: Vieira Neto
authors.forename: Luiz Eduardo A
authors.initials: LE
authors.lastname: Wildemberg
authors.forename: Leandro Machado
authors.initials: LM
authors.lastname: Colli
authors.forename: Margaret
authors.initials: M
authors.lastname: de Castro
authors.forename: Christina M
authors.initials: CM
authors.lastname: Takiya
authors.forename: Mônica R
authors.initials: MR
authors.lastname: Gadelha
mesh_terms: D000172:Acromegaly / Q000188:drug therapy / Q000378:metabolism*; D000236:Adenoma / Q000188:drug therapy / Q000378:metabolism*; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D010911:Pituitary Neoplasms; D017481:Receptors, Somatostatin / Q000378:metabolism*; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047908:Intracellular Signaling Peptides and Proteins; D017481:Receptors, Somatostatin; C574734:SSTR2 protein, human; C103265:aryl hydrocarbon receptor-interacting protein; D015282:Octreotide